C5 and paroxysmal nocturnal hemoglobinuria: While eculizumab and ravulizumab are also indicated for atypical hemolytic uremic syndrome (aHUS), pegcetacoplan is approved for patients with PNH who remain anemic despite C5 inhibitor therapy.